PM360: COVID-19’s Long-Lasting Impact on Clinical Trials

June 16, 2020

With COVID-19 impacting the conduct of clinical trials, a lot of discussion has been around what changes have allowed trials to continue recruitment. Protocol amendments and the use of technology are just a couple examples of trial aspects that have been drastically impacted by the pandemic, and are expected to see many implemented changes remain.

Read the full article here to learn more about how oncology CROs are uncovering solutions to make trials available to patients now and into the future amid current challenges.

Model Spotlight: Breast Cancer Clinical Update and Preclinical Plan

Based on the American Cancer Society 2026 estimates and survival statistics, as of October 2026, developments in antibody-drug conjugates (ADCs), ...

Read more +

Advancing Preclinical Research in Gynecologic Cancers

Gynecologic cancers, including endometrial and ovarian cancers, remain areas of high unmet need. Advances in targeted therapy, immunotherapy, ...

Read more +

History of CAR T-cells and Their Continued Use in Hematological Malignancies to Advance Next-Generation Therapies

CAR T-cell therapy originated in the late 1980s, first-generation constructs lacked adequate co-stimulatory signaling, causing poor CAR T-cell ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.